| Q36434758 | A Delphi Consensus Approach to Challenging Case Scenarios in Moderate-to-Severe Psoriasis: Part 1 |
| Q30713544 | A systematic review of validated methods for identifying patients with rheumatoid arthritis using administrative or claims data |
| Q36746012 | Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions |
| Q64123686 | An Observational Study of Cardiovascular Risks Associated with Rheumatoid Arthritis Therapies: A Comparison of Two Analytical Approaches |
| Q35381990 | An external validation study reporting poor correlation between the claims-based index for rheumatoid arthritis severity and the disease activity score. |
| Q55008598 | Analysis of Drug Effects on Primary Human Coronary Artery Endothelial Cells Activated by Serum Amyloid A. |
| Q36726386 | Atherosclerosis and inflammation: insights from rheumatoid arthritis |
| Q88917533 | Cardiovascular Safety of Biologics and JAK Inhibitors in Patients with Rheumatoid Arthritis |
| Q33713206 | Cardiovascular case fatality in rheumatoid arthritis is decreasing; first prospective analysis of a current low disease activity rheumatoid arthritis cohort and review of the literature |
| Q26823443 | Cardiovascular comorbidity in rheumatic diseases: a focus on heart failure |
| Q33943374 | Cardiovascular complications of rheumatoid arthritis: assessment, prevention, and treatment |
| Q36757060 | Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study |
| Q34081242 | Cardiovascular involvement in autoimmune diseases |
| Q33806651 | Cardiovascular morbidity and mortality in rheumatoid arthritis |
| Q38260198 | Cardiovascular risk and the use of biologic agents in rheumatoid arthritis |
| Q26738461 | Cardiovascular risk assessment in rheumatoid arthritis - controversies and the new approach |
| Q36361147 | Cardiovascular risk in rheumatoid arthritis: comparing TNF-α blockade with nonbiologic DMARDs |
| Q37956137 | Cardiovascular safety of biologic therapies for the treatment of RA. |
| Q37257008 | Celecoxib and sulfasalazine had negative association with coronary artery diseases in patients with ankylosing spondylitis: A nation-wide, population-based case-control study |
| Q37026106 | Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials? |
| Q38401848 | Decreased Cardiovascular Mortality in Patients with Incident Rheumatoid Arthritis (RA) in Recent Years: Dawn of a New Era in Cardiovascular Disease in RA? |
| Q36241707 | Effects of Methotrexate on Carotid Intima-media Thickness in Patients with Rheumatoid Arthritis. |
| Q40061090 | Incidence of comprehensive hospitalization due to infection, cardiovascular disease, fractures, and malignancies in patients with rheumatoid arthritis |
| Q37245192 | Infliximab improves vascular stiffness in patients with rheumatoid arthritis |
| Q38026796 | Lipid paradox in rheumatoid arthritis: changes with rheumatoid arthritis therapies |
| Q37704498 | Low-dose prednisolone treatment of early rheumatoid arthritis and late cardiovascular outcome and survival: 10-year follow-up of a 2-year randomised trial. |
| Q26776111 | MIF: Implications in the Pathoetiology of Systemic Lupus Erythematosus |
| Q35243557 | No increased risk of myocardial infarction among patients with ulcerative colitis or Crohn's disease |
| Q37079259 | Non-steroidal anti-inflammatory drug use does not appear to be associated with increased cardiovascular mortality in patients with inflammatory polyarthritis: results from a primary care based inception cohort of patients. |
| Q38098935 | Novel risk factors for cardiovascular disease in rheumatoid arthritis |
| Q24235971 | Pain management for rheumatoid arthritis and cardiovascular or renal comorbidity |
| Q92771536 | Pathogenesis of ischaemic and non-ischaemic heart diseases in rheumatoid arthritis |
| Q38612651 | Prevention of Stroke in Rheumatoid Arthritis |
| Q37014117 | Primer: administrative health databases in observational studies of drug effects--advantages and disadvantages |
| Q24630655 | Protective effect of methotrexate in patients with rheumatoid arthritis and cardiovascular comorbidity |
| Q31005025 | Protective effects of methotrexate against ischemic cardiovascular disorders in patients treated for rheumatoid arthritis or psoriasis: novel therapeutic insights coming from a meta-analysis of the literature data |
| Q40386790 | Relationship between exposure to tumour necrosis factor inhibitor therapy and incidence and severity of myocardial infarction in patients with rheumatoid arthritis. |
| Q37632485 | Relationship between tumor necrosis factor-α inhibitors and cardiovascular disease in psoriasis: a review |
| Q35377706 | Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease |
| Q37894193 | TNF alpha antagonist therapy and safety monitoring |
| Q33848290 | The effect of anti-rheumatic medications for coronary artery diseases risk in patients with rheumatoid arthritis might be changed over time: A nationwide population-based cohort study. |
| Q35135831 | The effects of tumour necrosis factor inhibitors, methotrexate, non-steroidal anti-inflammatory drugs and corticosteroids on cardiovascular events in rheumatoid arthritis, psoriasis and psoriatic arthritis: a systematic review and meta-analysis. |
| Q35092457 | The impact of traditional cardiovascular risk factors on cardiovascular outcomes in patients with rheumatoid arthritis: a systematic review and meta-analysis. |
| Q33892790 | The risk of acute coronary syndrome in rheumatoid arthritis in relation to tumour necrosis factor inhibitors and the risk in the general population: a national cohort study |
| Q93215244 | Therapeutic Approaches Targeting Inflammation in Cardiovascular Disorders |
| Q37808889 | Tumour necrosis factor antagonists and the risk of cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review |
| Q35954625 | What effects might anti-TNFalpha treatment be expected to have on cardiovascular morbidity and mortality in rheumatoid arthritis? A review of the role of TNFalpha in cardiovascular pathophysiology. |
| Q84815164 | [Cardiovascular comorbidity and its risk factors in rheumatoid arthritis] |
| Q85589116 | [Risk of atherosclerosis mediated by inflammation in rheumatoid arthritis] |